KRAS and non-small cell lung carcinoma: Current guidelines in the US state that patients with metastatic CRC being considered for EGFR-targeted therapies should be tested for KRAS and BRAF mutations [18], and recommend EGFR testing for patients with advanced NSCLC to predict response to first-line TK inhibitors [19,20].